Aegis Pharma

Aegis Therapeutics is a drug delivery technology company that specializes in enhancing the bioavailability and stability of therapeutic agents through non-invasive routes. The company's core technology, Intravail, is a collection of chemically synthesized transmucosal absorption enhancers that allow for the systemic delivery of peptides, proteins, and small molecules via nasal, oral, or ocular administration. Aegis was acquired by Neurelis in 2019, primarily to integrate the Intravail technology into Neurelis's lead product, Valtoco (diazepam nasal spray), for the treatment of seizure clusters. Beyond neurology, the company's platforms like ProSorb and SoluSorb are designed to improve the performance of various injectable and topical drug formulations.